Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.38
+1.3%
$0.43
$0.24
$2.53
$22.26M0.91914,684 shs432,781 shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$10.10
-0.8%
$8.98
$4.80
$18.13
$387.10M1.49690,934 shs270,389 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$16.52
-1.4%
$14.79
$2.80
$8.97
$595.68M0.6337,931 shs881,491 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.86
+49.6%
$0.45
$0.13
$2.96
$361.01M2.044.39 million shs38.11 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
0.00%-1.04%-21.15%+30.99%-71.21%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%0.00%0.00%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
0.00%+2.21%0.00%+93.71%-27.43%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%-9.23%+22.92%+29.06%+81.54%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.00%+77.83%+742.27%+246.70%+107.60%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioAtla, Inc. stock logo
BCAB
BioAtla
2.7275 of 5 stars
3.32.00.00.03.12.50.6
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
3.1841 of 5 stars
4.12.00.00.01.43.30.6
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.9713 of 5 stars
4.35.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
2.50
Moderate Buy$5.001,212.34% Upside
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00
N/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
2.14
Hold$15.8657.08% Upside
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.60
Moderate Buy$5.6397.01% Upside

Current Analyst Ratings Breakdown

Latest SBTX, BCAB, GRCL, ITOS, and VOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Outperform
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.00
5/28/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$10.00 ➝ $12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.00
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/14/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$47.00 ➝ $9.00
5/13/2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$15.00 ➝ $8.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$11M2.02N/AN/A$0.25 per share1.52
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$60K12,415.83N/AN/A$2.95 per share3.47
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
$35M11.04N/AN/A$16.16 per share0.62
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.51N/AN/AN/AN/AN/AN/AN/A

Latest SBTX, BCAB, GRCL, ITOS, and VOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.28-$0.29-$0.01-$0.26N/AN/A
4/28/2025Q1 2025
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
2.35
2.35
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.02
7.73
7.73
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
N/A
14.13
14.13
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/A
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
97.16%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
11.50%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
28.00%
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
12.50%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
6058.42 million51.70 millionOptionable
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
31472.68 million52.33 millionOptionable
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
9038.27 million33.49 millionOptionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140124.96 million65.45 millionNot Optionable

Recent News About These Companies

HC Wainwright Predicts Weaker Earnings for Vor Biopharma
HC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"
Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright
Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500
Vor Biopharma Inc. Stock Grades - Barron's

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$0.38 +0.00 (+1.30%)
As of 03:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Gracell Biotechnologies stock logo

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

iTeos Therapeutics stock logo

iTeos Therapeutics NASDAQ:ITOS

$10.10 -0.08 (-0.74%)
As of 03:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$16.52 -0.23 (-1.37%)
As of 07/3/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.86 +0.95 (+49.74%)
As of 03:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.